肾动脉支架置入术联合规范药物治疗对粥样硬化性肾动脉狭窄患者的疗效
2016-04-01李彬彭猛蒋雄京董徽邹玉宝宋雷张慧敏吴海英杨跃进高润霖
李彬,彭猛,蒋雄京,董徽,邹玉宝,宋雷,张慧敏,吴海英,杨跃进,高润霖
肾动脉支架置入术联合规范药物治疗对粥样硬化性肾动脉狭窄患者的疗效
李彬,彭猛*,蒋雄京,董徽,邹玉宝,宋雷,张慧敏,吴海英,杨跃进,高润霖
摘要
关键词肾动脉梗阻;支架;肾小球滤过率;药物治疗
作者单位:100037 北京市,北京协和医学院 中国医学科学院 国家心血管病中心 阜外医院 高血压中心
Efficacy of Renal Artery Stenting Combining Optimal Drug Therapy in Patients With Atherosclerotic Renal Artery Stenosis
LI Bin, PENG Meng, JIANG Xiong-jing, DONG Hui, ZOU Yu-bao, SONG Lei, ZHANG Hui-min, WU Hai-ying, YANG Yue-jin, GAO Ren-lin.
Department of Cardiology, Cardiovascular Institute and Fu Wai Hospital, CAMS and PUMC, Beijing (100037), China
Corresponding Author: JIANG Xiong-jing, Email:jxj103hotmail.com
Abstract
Objective: To evaluatethe efficacy of renal artery stenting combining optimal drug therapy in patients with atherosclerotic renal artery stenosis.
Methods: This is a prospective cohort study for patients who received percutaneous renal artery stenting in our hospital from 2011-09 to 2013-03.All patients had confirmed diagnosis of atherosclerotic renal artery stenosis combing hypertension and/or renal functional damage.Thepatients received optimal drug therapy for anti-platelet and blood pressure, lipids, glucose controlling, and they were followed-up for at least 12 months to observe the improvement of blood pressure and renal function.
Results: There were 149 patients at the mean age of (61.54 ± 9.63) years and 185 renal artery stenosis with stent implantation; the average stenosis rate was (83.11±7.30) % and the success rate of operation was 99.32% (148/149).During follow-up period, the patients had increased estimated glomerular filtration rate (GFR) compared to base line from (76.49 ± 22.50) ml/(min·1.73 m2) to (84.09 ± 28.79) ml/(min·1.73 m2), P<0.05 and decreased 24 h urinary protein from 0.1(IQR 0.02, 0.5) g to 0.04 (IQR0.01, 0.11)g, P<0.001; less type of drug therapy for hypertension from 2.22 to 1.56, P<0.05, decreasedclinical and 24h dynamic systemic/diastolic blood pressure from (153.4 ± 15.6)/(83.77 ± 12.60) mmHg to (134.6 ± 14.4)/ (73.57 ± 9.12) mmHg and from (143.32 ± 19.87)/(80.51 ± 11.33) mmHg to (124.44 ± 14.90)/(69.09 ± 9.49) mmHg, all P<0.05.
Conclusion:Renal artery stenting combining optimal drug therapy may improve blood pressure controlling and renal function in strictly selected patients with atherosclerotic renal artery stenosis.
Key words Renal artery obstruction; Stent; Glomerular filtration rate; Drug therapy
(Chinese Circulation Journal, 2016,31:122.)
动脉粥样硬化是肾动脉狭窄的常见病因[1],主要累及肾动脉开口及近段,呈进行性加重,常引起肾血管性高血压及肾功能损害。肾动脉血运重建是治疗肾动脉狭窄的主要措施,经皮肾动脉支架置入术(percutaneous renal artery stenting,PRAS)以其创伤小、安全性高的优势,正成为粥样硬化性肾动脉狭窄(atherosclerotic renal artery stenosis,ARAS)的首选治疗方法,但其临床疗效仍有很大争议[2]。近年发表的随机对照研究显示,与单纯药物治疗相比,PRAS并不能带来额外的获益[3-5]。但这些随机对照研究都存在一些缺陷[6]:如平均每个中心每年入选的病例数目较少;入选标准过于宽泛,未确定行支架置入术的肾动脉是否存在功能意义。在介入标准严格、流量大的医疗中心,临床实践结果表明PRAS安全有效[7, 8]。我院作为国际上最大的PRAS中心之一,对ARAS有严格的介入治疗标准和规范的药物治疗方案,自2003年起,每年PRAS手术量可达70例以上,2008年后每年150例以上。本研究旨在评估PRAS联合规范药物治疗对伴有功能意义的ARAS患者的临床疗效。
1 资料与方法
研究对象:本研究为前瞻性队列研究,研究对象为2011-09至2013-03于我院行PRAS的ARAS患者。……
